Brailoiu E, Deliu E, Sporici RA, Benamar K, Brailoiu GC. HIV-1-Tat excites cardiac parasympathetic neurons of nucleus ambiguus and triggers prolonged bradycardia in conscious rats.
-The mechanisms of autonomic imbalance and subsequent cardiovascular manifestations in HIV-1-infected patients are poorly understood. We report here that HIV-1 transactivator of transcription (Tat, fragment 1-86) produced a concentration-dependent increase in cytosolic Ca 2ϩ in cardiac-projecting parasympathetic neurons of nucleus ambiguus retrogradely labeled with rhodamine. Using store-specific pharmacological agents, we identified several mechanisms of the Tat-induced Ca 2ϩ elevation: 1) lysosomal Ca 2ϩ mobilization, 2) Ca 2ϩ release via inositol 1,4,5-trisphosphate-sensitive endoplasmic reticulum pools, and 3) Ca 2ϩ influx via transient receptor potential vanilloid type 2 (TRPV2) channels. Activation of TRPV 2, nonselective cation channels, induced a robust and prolonged neuronal membrane depolarization, thus triggering an additional P/Q-mediated Ca 2ϩ entry. In vivo microinjection studies indicate a dose-dependent, prolonged bradycardic effect of Tat administration into the nucleus ambiguus of conscious rats, in which neuronal TRPV 2 played a major role. Our results support previous studies, indicating that Tat promotes bradycardia and, consequently, may be involved in the QT interval prolongation reported in HIVinfected patients. In the context of an overall HIV-dependent autonomic dysfunction, these Tat-mediated mechanisms may account for the higher prevalence of sudden cardiac death in HIV-1-infected patients compared with general population with similar risk factors. Our results may be particularly relevant in view of the recent findings that significant Tat levels can still be identified in the cerebrospinal fluid of HIV-infected patients with viral load suppression due to efficient antiretroviral therapy. autonomic cardiovascular regulation; cytosolic Ca 2ϩ , endoplasmic reticulum; nucleus ambiguus; transient receptor potential vanilloid type 2 INFECTION WITH THE HUMAN IMMUNODEFICIENCY virus type 1 (HIV-1) leads to the development of HIV-dependent neurological and cardiovascular disorders (25) . Autonomic imbalance and arrhythmias are often observed in HIV patients (18, 48) . The mechanisms underlying autonomic dysregulation in HIVinfected patients are poorly understood. HIV has been proposed to alter the function of hypothalamic nuclei involved in sympathetic regulation and of sympathetic ganglia (18) . Cardiac vagal efferent pathways are also impaired in HIV (18) .
Peripheral neuropathy has been denoted as a putative cause of parasympathetic deregulation because of its frequent association with dysautonomia in HIV (48) .
The HIV invades the brain soon after systemic infection, targeting microglia and perivascular macrophages, while replicating in astrocytes (41) . Whereas neurons are resistant to HIV infection, the infected brain cells may release viral components and neurotoxins that alter neuronal function (41) . Antiretroviral therapy is efficient in reducing the viral load, but cannot prevent production of early viral proteins (50) . Since the alteration of the sympathovagal balance occurs early in HIV infection and evolves with disease progression (4, 40) , the early HIV proteins may contribute to autonomic impairment.
Among the early viral components, the transactivator of transcription (Tat) protein is an important factor in the HIVinduced pathogenesis of AIDS, contributing to HIV-associated neurological and cardiovascular impairment (27, 49) . Tat is expressed at high levels in the brains of HIV-1-infected individuals and has been reported to alter neuronal function (35) . Moreover, Tat has recently been identified in the cerebrospinal fluid of patients with suppressed viremia due to efficient antiretroviral treatment (32) . Transgenic mice expressing Tat in the myocardium present with bradycardia (22) . The first 72 residues of Tat, encoded by the first exon, are critically involved in Tat neuronal effects (35) . In this study, we investigate the effect of a widely used Tat fragment (1-86) (35) , referred to as Tat, on cardiac preganglionic neurons of nucleus ambiguus, which are key regulators of the parasympathetic cardiac tone (38) .
MATERIALS AND METHODS
Ethical approval. Animal protocols were approved by the Institutional Animal Care and Use Committee from Thomas Jefferson University and Temple University. All efforts were made to minimize the number of animals used and their suffering.
Chemicals. All chemicals were from Sigma-Aldrich (St. Louis, MO), unless otherwise mentioned. Tat protein (1-86) was from Prospec (East Brunswick, NJ). HIV-1 Tat was heat-inactivated by repeated (10 times) heating (75°C for 30 s) and cooling (4°C for 1 min), as previously reported (10) .
Animals. Neonatal and adult Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) were used in this study. Neonatal (1-2 days old) rats of either sex were used for retrograde tracing and neuronal culture, and adult male rats (250 -300 g) were used for cardiovascular measurements.
Neuronal labeling and culture. Preganglionic cardiac vagal neurons of nucleus ambiguus were retrogradely labeled by intrapericardial injection of rhodamine [X-rhodamine-5-(and-6)-isothiocyanate; 5(6)-XRITC], 40 l, 0.01% (Invitrogen, Carlsbad, CA), as reported by Brailoiu et al. (8, 9, 12) . Medullary neurons were dissociated and cultured 24 h after rhodamine injection, as previously described (8, 9, 12) . In brief, the brains were quickly removed and immersed in ice-cold Hanks' balanced salt solution (HBSS; Mediatech, Manassas, VA). Neonate rats were euthanized by decapitation. The ventral side of the medulla (containing nucleus ambiguus) was dissected and minced, and the cells were subjected to enzymatic and mechanical dissociation. Cells were filtered using a sterile 40-m filter/cell strainer (Falcon, Fisher Scientific, Waltham, MA) and were plated on glass coverslips in Neurobasal-A medium (Invitrogen) containing 1% GlutaMax (Invitrogen), 2% antibiotic-antimycotic (Mediatech, Herndon, VA), and 10% FBS. Cultures were maintained at 37°C in a humidified atmosphere with 5% CO 2. Cytosine ␤-arabino furanoside (1 M) was added to the culture to inhibit glial cell proliferation (52) .
Calcium imaging. Measurements of intracellular Ca 2ϩ concentration, [Ca 2ϩ ]i were performed as previously described (8, 9, 12 (28) . Measurement of membrane potential. The relative changes of neuronal membrane potential were evaluated using bis-(1,3-dibutylbarbituric acid)-trimethine-oxonol, DiBAC4(3), a voltage-sensitive dye, as reported (9, 12) . Neurons were incubated for 30 min in HBSS containing 0.5 mM DiBAC4(3), and the fluorescence was monitored at 0.17 Hz (excitation/emission 480 nm/540 nm). Calibration of DiBAC4(3) fluorescence was performed using the Na ϩ -K ϩ ionophore gramicidin in Na ϩ -free physiological solution and various concentrations of K ϩ and N-methylglucamine, as described previously (13) . Surgical procedures. Adult male Sprague-Dawley rats were anesthetized with a mixture of ketamine hydrochloride (100 -150 mg/kg) and acepromazine maleate (0.2 mg/kg), as reported previously (5, 9, 12) . Animals were placed into a stereotaxic instrument; a guide C315G cannula (PlasticsOne, Roanoke, VA) was bilaterally inserted into the nucleus ambiguus. The stereotaxic coordinates for identification of nucleus ambiguus were 12.24 mm posterior to bregma, 2.1 mm from midline, and 8.2 mm ventral to the dura mater. A C315DC cannula dummy (PlasticsOne) was used to prevent contamination. For transmitter implantation, a 2-cm-long incision was made along the linea alba. A calibrated transmitter (E-mitters, Series 4000; Mini Mitter, Sunriver, OR) was inserted in the intraperitoneal space, as previously described (9, 12) . Subsequently, the abdominal musculature and dermis were sutured independently, and animals returned to individual cages.
Telemetric heart rate monitoring. The signal generated by transmitters was collected via series 4000 receivers (Mini Mitter, Sunriver, OR), as previously described (9, 12) . VitalView software (Mini Mitter) was used for data acquisition. Each data point represents the average of heart rate per 30 s.
Noninvasive blood pressure measurement. In rats with cannula inserted into the nucleus ambiguus, blood pressure was noninvasively measured using a volume pressure recording sensor and an occlusion tail-cuff (CODA System, Kent Scientific, Torrington, CT), as described previously (12) . One week after the insertion of the cannula, rats were exposed to handling and training every day for 1 wk. The maximum occlusion pressure was 200 mmHg, minimum pressure was 30 mmHg, and deflation time was 10 s. Two measurements were done per 30 s (one cycle), and the average was used to calculate heart rate and systolic, diastolic, and mean arterial blood pressure. Ten acclimatization cycles were done before starting the experiments.
Microinjection into nucleus ambiguus. One week after surgery (telemetric studies) or after another week of training (tail-cuff measurements), bilateral microinjections into the nucleus ambiguus were carried out using the C315I internal cannula (33 gauge, PlasticsOne) and a Neuros Hamilton syringe, model no. 7000.5 KH SYR, without animal handling. In the tail-cuff method, trained rats were in the animal holder for the duration of the experiment. For recovery, at least 2 h were allowed between two injections. Injection of L-glutamate (5 mM, 50 nl) was used for the functional identification of nucleus ambiguus (8, 9) .
Statistical analysis. Data were expressed as means Ϯ SE. One-way ANOVA followed by post hoc analysis using Bonferroni and Tukey tests was used to evaluate significant differences between groups. P Ͻ 0.05 was considered statistically significant.
RESULTS

HIV-1 Tat increases cytosolic Ca
2ϩ concentration in cardiac preganglionic neurons of nucleus ambiguus. In rhodamine-labeled neurons, Tat (500 nM) induced a fast increase in intracellular Ca 2ϩ concentration, [Ca 2ϩ ] i , followed by a rapid decrease and a plateau maintained at half maximal level ( In vitro systems test Tat effects at concentrations varying between 100 and 500 nM (1, 21, 46, 56) . Since robust responses were elicited with 500 nM Tat, similar to previous reports (1, 21, 56), we used this concentration in our following experiments.
Tat elicits Ca 2ϩ influx in cardiac vagal neurons. We used a pharmacological approach to test the involvement of several Ca 2ϩ -permeable ion channels to Tat-induced Ca 2ϩ increase in vagal neurons. Inhibition of N-type Ca 2ϩ channels with -conotoxin GVIA (100 nM, 20 min) did not significantly modify the shape of the Ca 2ϩ signal produced by Tat (500 nM) in rhodamine-labeled preganglionic neurons ( Fig. 2A) . The amplitude and the area under curve were similarly unaffected: the amplitude of the Tat-induced response was 647 Ϯ 6.3 nM (n ϭ 6) in the absence vs. 638 Ϯ 7.3 nM (n ϭ 6) in the presence of N-type Ca 2ϩ channel blocker (Fig. 2B) ; the areas under curve were 2,463 Ϯ 41 nM ϫ min and 2,397 Ϯ 54 nM ϫ min, respectively (Fig. 2B) . Pretreatment of neurons with -conotoxin MVIIC (100 nM, 20 min), a blocker of P/Q-type of Ca 2ϩ channels, slightly reduced the amplitude of the Tatdependent Ca 2ϩ elevation (⌬[Ca 2ϩ ] i was 541 Ϯ 5.7 nM; n ϭ 6), and significantly diminished the area under the curve, which measured 1,603 Ϯ 27 nM ϫ min in this case (Fig. 2B) . Since transient receptor potential vanilloid 2 (TRPV 2 ) is a Ca 2ϩ -permeable nonselective cation channel expressed in the nucleus ambiguus (34), we tested the effect of TRPV 2 inhibitor tranilast (44, 45) . In the presence of tranilast (100 M, 20 min), Tat elicited a significantly blunted Ca 2ϩ response, with a lower peak and shorter-duration plateau (Fig. 2A) ; the amplitude measured 411 Ϯ 5.1 nM (n ϭ 6), and the area under the curve was 680 Ϯ 19 nM ϫ min (Fig. 2B) . When both TRPV 2 and P/Q channels were inhibited, Tat no longer elicited a plateau phase, and the initial transient increase in [Ca 2ϩ ] i was additionally reduced ( Fig. 2A) . ⌬ [Ca 2ϩ ] i was 359 Ϯ 4.7 nM (n ϭ 6), and the area under the curve was 447 Ϯ 17 nM ϫ min (Fig.  2B) . The functional presence of Ca 2ϩ -permeable TRPV 2 in rhodamine-labeled cardiac vagal neurons was detected by the Ca 2ϩ response produced by application of TRPV 2 agonist probenecid (100 M) (2). The response to probenecid was abolished in Ca 2ϩ -free saline or by the TRPV 2 blocker tranilast (100 M, 20 min) (Fig. 3, A and B ] i was 79 Ϯ 2.4 nM, n ϭ 6 neurons (Fig. 4, A and B) . Blocking ryanodine receptors with ryanodine ] i was 371 Ϯ 3.9 nM; n ϭ 6). In the presence of xestospongin C (10 M, 15 min), a blocker of inositol 1,4,5-trisphosphate (IP 3 ) receptors (IP 3 R), rhodamine-labeled cardiac vagal neurons responded to Tat with a greatly diminished increase in [Ca 2ϩ ] i , by 81 Ϯ 1.8 nM (n ϭ 6) at the peak of the response (Fig. 4, A and B) . A significant reduction in the Tat-mediated response was also observed in the presence of bafilomycin A1 (1 M, 1 h), a V-type ATPase that inhibits lysosomal acidification (6); ⌬[Ca 2ϩ ] i was 176 Ϯ 3.7 nM, n ϭ 6 (Fig. 4, A and B) . Pretreatment with both bafilomycin and xestospongin C largely abolished the Ca 2ϩ increase produced by Tat (⌬[Ca 2ϩ ] i ) was 16 Ϯ 2.3 nM; n ϭ 6 (Fig. 4, A and B) . Tat produces a concentration-dependent depolarization of cardiac vagal neurons. Tat (500 nM) robustly depolarized cardiac-projecting parasympathetic neurons retrogradely labeled with rhodamine, an effect that lasted for the duration of the experiment (Fig. 5A) . Conversely, heat-inactivated Tat (500 nM) produced negligible effects on membrane potential (⌬voltage was 0.83 Ϯ 0.1 mV, Fig. 5, A and B) . Increasing concentrations of Tat (5 nM, 50 nM, 500 nM, and 5,000 nM) induced neuronal depolarizations with amplitudes of 0.6 Ϯ 0.4 mV, 4.7 Ϯ 0.6 mV, 11.9 Ϯ 0.8 mV, and 14.3 Ϯ 1.1 mV, respectively (Fig. 5B) , and a calculated EC 50 of 101 nM. The responses to the latter three concentrations of Tat were significant (n ϭ 6 neurons per each condition; P Ͻ 0.00001).
Tat-induced depolarization involves TRPV 2 activation. Treatment of the neurons with BAPTA-AM (200 M, 20 min), a fast Ca 2ϩ chelator, markedly reduced the amplitude and the duration of Tat-induced neuronal depolarization (Fig. 6A) . In neurons pretreated with the TRPV 2 inhibitor tranilast (100 M, 20 min; Fig. 6A ), Tat produced a similar, strongly diminished response. The amplitude of the depolarization elicited by Tat (500 nM) was reduced from 11.9 Ϯ 0.8 mV to 4.2 Ϯ 0.7 mV in the presence of BAPTA and to 4.1 Ϯ 0.8 mV in the presence of tranilast, while the area under the curve decreased from 73.1 Ϯ 5.4 mV ϫ min to 7.68 Ϯ 0.41 mV ϫ min and to 6.65 Ϯ 0.39 mV ϫ min, respectively (Fig. 6B) .
Microinjection of Tat into the nucleus ambiguus produces bradycardia in conscious rats. In conscious, freely moving rats bearing cannulas implanted into the nucleus ambiguus, microinjection of control saline (50 nl) produced negligible effects on heart rate, monitored telemetrically. Microinjection of L-glutamate (5 mM, 50 nl) elicited bradycardia, without a change in blood pressure (Fig. 7A) , indicating the correct placement of the cannula into the nucleus ambiguus (8, 9, 17) . Two hours after L-glutamate administration, microinjection of Tat (500 fmol/50 nl) triggered a sharp and sustained decrease in heart rate (Fig. 7A) . Similar responses were recorded using the tail-cuff method (Fig. 7A) . The tail-cuff method allowed measurement of blood pressure; as shown in Fig. 7A , microinjection of Tat into the nucleus ambiguus had no effect on blood pressure. Heat inactivation of Tat prevented its bradycardic effects (Fig. 7A) . Tat (5 fmol, 50 fmol, and 500 fmol/50 nl) decreased the heart rate of conscious rats by 6 Ϯ 1.7 beats per min (bpm), 26 Ϯ 8 bpm, and 68 Ϯ 2.1 bpm, respectively (Fig. 7B) . Only the latter two effects were statistically significant (P Ͻ 0.00001). Administration of heat-inactivated Tat (500 fmol/50 nl) did not result in a significant change in heart rate (4 Ϯ 0.7 bpm). Five animals were used per each treatment group. In vivo studies evaluating Tat effects in the brain use Tat at a concentration of 3 or 4 g/l, which is Ͼ1,000 times higher than that commonly used in vitro (36, 60) . Similarly, microinjection in the rat nucleus ambiguus of higher concentrations of Tat (5-500 fmol/50 nl, i.e., 0.1-10 M) elicited the bradycardic responses. The explanation may reside in the fact that Tat may be locally diluted upon microinjection (60) or that Tat is not only sensitive to oxidation, but also is particularly sticky, able to bind even to silanized glass surfaces (as in the syringe barrel and needle used in stereotaxic injections) (36) .
Measuring actual levels of Tat in the extracellular space in the central nervous system has proven difficult because of the lack of successful ELISA strategies and because native Tat is incredibly sensitive to oxidation. Nanomolar levels of Tat have been detected in the sera of HIV-infected patients, but these values may be underestimated, since Tat can be trapped by heparan sulfate expressed on the cell surfaces (46) . However, patients with suppressed viremia due to effective antiretroviral treatment still present nanomolar levels of Tat in the cerebrospinal fluid (32) . This concentration is expected to be higher near productively infected cells. As such, although Tat levels in situ (i.e., in the brain extracellular space) remain to be determined, it is conceivable that levels sufficient to promote neuronal activation may well be achieved near HIV-1-infected glia cells.
Tat-induced bradycardia is mediated by TRPV 2 . Microinjection of TRPV 2 antagonist tranilast (100 M, 50 nl) alone produced a negligible increase in heart rate ( Fig. 8A) , with a mean amplitude of 9 Ϯ 0.7 bpm (n ϭ 5) and with an area under the curve of 36 Ϯ 4.1 bpm ϫ min (Fig. 8B) . Concomitant microinjection of tranilast and Tat (500 fmol/50 nl) drastically reduced the amplitude and duration of Tat-induced bradycardic effect (Fig. 8A) . In the presence of tranilast, Tat decreased the heart rate by 53 Ϯ 2.9 bpm (n ϭ 5), compared with a decrease by 68 Ϯ 2.1 bpm produced by Tat alone (n ϭ 5 rats). The areas under the curve were more dramatically affected: 52 Ϯ 4.3 bpm ϫ min after combined tranilast and Tat administration, compared with 432 Ϯ 8.3 bpm ϫ min produced by Tat alone (Fig. 8B) .
DISCUSSION
HIV-1 Tat is a 72(86)-101(104)-amino acid regulatory protein, essential for viral transcription and replication; the first 56 residues of Tat are well conserved, indicating important functional roles (20, 49) . The cysteine-rich region (residues 22-37) A: representative changes in membrane potential elicited by Tat (500 nM) or heatinactivated Tat (500 nM) in rhodamine-labeled neurons. B: concentration-response curve indicating the effect of Tat (5-5,000 nM; EC50 ϭ 101 nM) and heat-inactivated Tat (500 nM) on the resting membrane potential of cardiac vagal neurons; P Ͻ 0.00001 compared with resting membrane potential (*) or to the effect of 500 nM Tat (#). and the basic domain (residues 31-61) play major roles in Tat-induced neurotoxic and excitatory effects (35) . Upon release by infected microglia, macrophages, and astrocytes, Tat targets uninfected neurons to trigger Ca 2ϩ responses and depolarization (7, 10, 35) . These mechanisms have been implicated in both Tat-mediated neuronal responses and HIV-induced neurotoxicity (43, 46, 49) .
The first observation of the present study is that Tat (fragment 1-86) produced a robust increase in [Ca 2ϩ ] i of cardiac vagal neurons, characterized by an initial transitory peak with high amplitude, followed by a long-lasting, smaller plateau. Next, we identified that the sustained phase of the Tat-induced effect on [Ca 2ϩ ] i was mostly dependent on Ca 2ϩ entry via TRPV 2 nonselective cation channels and only partially mediated by P/Q-type of voltage-activated Ca 2ϩ channels. We and others reported a major role of P/Q-type of Ca 2ϩ current in the physiology of cardiac parasympathetic ambiguus neurons (9, 11, 12, 31) . A Tat-mediated P/Q Ca 2ϩ current has also been described in suprachiasmatic nucleus neurons (19) . Nonetheless, not much is known about the TRPV 2 function in nucleus ambiguus neurons, despite the strong expression of this type of channel at the level of the nucleus ambiguus (34) . Similarly, little evidence points to a contribution of transient receptor potential channels to Tat-induced neuronal effects.
Conversely, the short-lived and high-amplitude component of the Tat-triggered Ca 2ϩ response consisted of Ca 2ϩ influx via TRPV 2 and Ca 2ϩ release from two separate intracellular Ca 2ϩ pools: the lysosomes and the IP 3 -sensitive endoplasmic reticulum stores. Tat has been reported to promote IP 3 formation and/or IP 3 R-mediated Ca 2ϩ mobilization from the endoplasmic reticulum in human fetal neurons and astrocytes (29) , human macrophages (37), and human cerebrocortical terminals (23) . Our finding that Tat mobilizes lysosomal Ca 2ϩ stores correlates well with the fact that this protein enters neurons rapidly via receptor-mediated endocytosis, altering the endolysosomal structure and function (15, 30) . Since TRPV 2 are Ca 2ϩ -permeable nonselective cation channels modulated by Ca 2ϩ and by phosphatidylinositol-4,5-bisphosphate metabolism (39, 42) , we propose that HIV Tat acts first to mobilize intracellular Ca 2ϩ stores and that TRPV 2 stimulation occurs consequently (Fig. 9) .
Similar to other types of neurons (10, 35) , cardiac-projecting vagal neurons of nucleus ambiguus depolarized in response to Tat application, and the effect was concentration-dependent. The depolarization occurred rapidly and presented a sustained plateau that lasted for the entire duration of the experiments. Ca 2ϩ chelation or TRPV 2 inhibition produced likewise reductions of the initial amplitude and abolished the sustained phase of the depolarization. The residual Tat-mediated depolarizations had largely identical kinetics and amplitudes in the presence of BAPTA-AM or tranilast pretreatment, supporting a correlation of the Ca 2ϩ increase and TRPV 2 activation in the mechanism. A putative explanation of the residual depolarization observed with Tat in the presence of BAPTA may lie in the ability of Tat to depolarize the neuronal cell membrane when applied extracellularly to outside-out membrane patches, Fig. 7 . Tat microinjection into the nucleus ambiguus of conscious rats elicits a prolonged, dose-dependent decrease in heart rate. A: characteristic heart rate and blood pressure recordings after microinjection of saline, L-glutamate (L-Glu; 5 mM, 50 nl) and either Tat (500 fmol/50 nl) or boiled Tat (500 fmol/50 nl), obtained using the telemetric method (top) or the tail-cuff method (bottom). B: microinjection of Tat (5, 50, and 500 fmol) induces dose-dependent bradycardic responses, while heat-inactivated Tat (500 fmol) has negligible effects on heart rate; P Ͻ 0.00001 compared with basal heart rate (*) or to 500 fmol Tat (#). bpm, beats per min. Fig. 8 . Tat-induced bradycardia is TRPV2-dependent. A: representative heart rate recordings after intranucleus ambiguus administration of saline, L-glutamate (L-Glu; 5 mM/50 nl) and either Tat (500 fmol/50 nl), tranilast (Tran, 100 M/50 nl) or both Tat and tranilast. B: comparison of the effects on heart rate of the treatments mentioned in A, evaluated in terms of amplitude (top) and area under curve (AUC; bottom). *P Ͻ 0.00001 compared with microinjection of Tat (500 fmol/50 nl). and, thus, directly excite neurons on the cell surface (16) . Absence of extracellular Ca 2ϩ attenuated Tat-induced depolarization only by 43%, both in intact neurons and in outside-out patches (16) , which is consistent with the findings of our present study.
Our in vivo microinjection studies indicate that Tat administration into the nucleus ambiguus produced a strong and sustained decrease in heart rate, which was not accompanied by an effect on blood pressure. When TRPV 2 channels in the nucleus ambiguus were blocked by tranilast pretreatment, Tat elicited only a transient heart rate decrease, reduced in amplitude, indicating a major contribution of TRPV 2 in Tat-mediated prolonged bradycardia. Thus, we propose that Tat targets cardiac preganglionic neurons of the nucleus ambiguus to produce Ca 2ϩ release from lysosomal and endoplasmic reticulum IP 3 -sensitive Ca 2ϩ pools, resulting in intracellular Ca 2ϩ increase. Further, we infer that TRPV 2 activation occurs subsequently to Tat-induced stimulation of the intracellular cascade leading to IP 3 R-mediated Ca 2ϩ release (Fig. 9 ). TRPV 2 regulation by extracellular Ca 2ϩ and phosphoinositide 4,5-bisphosphate metabolism has been reported (39, 42) . In addition, TRPV 2 channels were recently shown to be activated downstream of a G protein-and PLC-mediated pathway (3, 42) . Furthermore, AT 1 R stimulation by ANG II promoted IP 3 R-mediated Ca 2ϩ elevation, which appeared to be implicated in the subsequent activation of TRPV 2 , since IP 3 R blockade prevented the TRPV 2 -dependent component of the Ca 2ϩ response (3). As such, mobilization of Ca 2ϩ from intracellular stores may precede and trigger Ca 2ϩ influx via TRPV 2 (3). Since TRPV 2 appeared to be implicated both in the Ca 2ϩ influx and in the depolarization elicited by Tat in cardiac vagal neurons, we propose that this depolarization was responsible for the activation of the P/Q-type of voltage-activated Ca 2ϩ channels (Fig. 9) . These intracellular events converge to neuronal activation, which is translated in vivo into a prolonged bradycardia (Fig. 9) .
Bradycardia is one of the factors that trigger QT interval prolongation and the consequent life-threatening polymorphic ventricular arrhythmia known as torsade de pointes (57) . HIVinfected patients have a higher prevalence of QT prolongation (47, 51) , along with HIV-dependent autonomic neuropathy (24, 59) . Emerging evidence indicates their primary association with HIV infection rather than with the anti-HIV therapy (14, 24) . Cardiovascular complications of antiretroviral treatment have been described (33, 61, 63) . Particularly, patients receiving antiretroviral drugs may be at increased risk for myocardial infarction (33, 61) . However, recent studies indicate that cardiovascular risk status, as estimated by Framingham risk score categories (Ͻ6% and Ն6%), remained relatively stable over 144-wk period in patients enrolled in ARIES (Atazanavir, Ritonavir, Induction with Epzicom Study; EPZ108859) (62) . ARIES was a large-phase IIIb/IV treatment-simplification clinical trial in which antiretroviral therapy-naive subjects who achieved virologic suppression by week 30 on a regimen of abacavir/lamivudine plus atazanavir/ritonavir were randomized to remain on their original regimen or discontinue the ritonavir component of the regimen for up to a total of 144 wk (53) (54) (55) . The effects of antiretroviral therapy on QT interval prolongation (14, 24) or on dysautonomia in HIV (14) were found insignificant. Conversely, greater QT interval duration has been reported in HIV-infected patients with asymptomatic autonomic neuropathy compared with HIV-infected patients without neurological disorder (59) , indicating that dysautonomia in HIV infection has a negative impact on cardiac function. Moreover, HIV-infected individuals are at a significantly higher risk for sudden cardiac death compared with the general population with similar risk factors (58) . Lethal arrhythmias account for as much as 20% of total sudden cardiac deaths in HIV-1-infected patients and are six times more prevalent in these patients than in the control population (58) . Of the sudden cardiac death victims with recent laboratory investigations, over half had undetectable viral loads (58); nonetheless, patients under controlled antiretroviral therapy showing viral load suppression both in the blood and cerebrospinal fluid still present significant levels of Tat in the cerebrospinal fluid (32) .
Perspectives and Significance
HIV-1 transactivator of transcription, or Tat, has several pleiotropic functions in addition to its transcriptional activity (27) . We report here that Tat produces a sustained bradycardia by targeting neurons of nucleus ambiguus that modulate the cardiac vagal tone. We characterize the underlying cellular mechanisms of Tat-induced activation of nucleus ambiguus neurons. Our findings provide a novel mechanism for the ]i activates transient receptor potential vanilloid type 2 (TRPV2) channels at the plasma membrane promoting cation entry (mostly Na ϩ and Ca 2ϩ ) and subsequent depolarization. Depolarization triggers activation of P/Q-type of voltage-activated Ca 2ϩ channels, resulting in an additional Ca 2ϩ influx. This cascade converges on cardiac vagal neuron activation, increase of parasympathetic outflow to the heart, and decrease in heart rate.
cardiac autonomic dysfunction reported in HIV-infected patients (4, 18, 26, 40) .
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